Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the launch of

BON

Pharvaris Presents Deucrictibant Clinical Data And Real-World HAE Treatment Satisfaction Data At ACAAI 2023 Annual Scientific Meeting

By Benzinga Newsdesk

November 9, 12:08 PM

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of two ePosters at

PHVS

XORTX Announces Completion Of Screening And Enrollment In Bridging Pharmacokinetics Study

By Benzinga Newsdesk

November 28, 8:01 AM

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat

TSXV:XRTX

Rumble Launches Free Livestreaming For Creators

Related Posts

JP Morgan Downgrades American Homes 4 Rent to Neutral, Announces $36 Price Target

Bon Natural Life Limited Launches Three New Cruciferous Vegetable-Based Powder Drinks

Pharvaris Presents Deucrictibant Clinical Data And Real-World HAE Treatment Satisfaction Data At ACAAI 2023 Annual Scientific Meeting

XORTX Announces Completion Of Screening And Enrollment In Bridging Pharmacokinetics Study